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Abdominal Organ Cluster Transplantation for the 
Treatment of Upper Abdominal Malignancies 
THOMAS E. STARZL, M.D., PH.D., SATORU TODO, M.D., ANDREAS TZAKIS, M.D., LUIS PODESTA, M.D., 
LUIS MIELES, M.D., ANTHONY DEMETRIS, M.D.: LEWIS TEPERMAN, M.D., RICK SELBY, M.D., 
WILLIAM STEVENSON, M.D., ANDREI STIEBER, M.D., ROBERT GORDON, M.D., and SHUNZABURO IWATSUKI, M.D. 
Ten patients with primary malignant tumors of the biliary tract, 
duodenum, or stomach and with secondary involvement of the 
liver underwent removal of most or all of the stomach, liver, 
pancreas, spleen, duodenum, proximal jejunum, terminal ileum, 
and ascending and transverse colon. The void in the upper ab-
domen was filled with an organ cluster graft consisting of the 
liver, pancreas, duodenum, and variable segments of proximal 
jejunum. Eight of the ten patients are alive after 3 to 9 months, 
all with good liver and pancreas function, and most with satis-
factory function of the gastrointestinal tract. One of the surviving 
patients was in the hospital for 4 months because of multiple 
enteric fistulas and infections; the other seven survivors were 
discharged after an average of 43 ± 17.61 (SD) days. Recurrent 
tumor has not been proved in any of the surviving recipients and 
is suspected in only one. The study of such cases should provide 
insight and guidelines applicable to other visceral transplantation 
procedures that may be attempted in the future. 
I N THE DEVELOPMENT OF THE human fetus, the liver and pancreas begin as ventral and dorsal diverticula 
from that portion of the foregut that later becomes 
the duodenum l (Fig. lA). The anatomic relationship of 
these organs becomes more complex with their differen-
tiation and rotation, but their intimacy, including the 
sharing of the terminal hepatic and pancreatic duct drain-
age into the duodenum, is not lost. Thus it is not surprising 
that malignant tumors developing at or near the original 
duodenal outpouchings are notoriously refractory to 
treatment, even if these are localized to a single organ. 
Tumors that originate in one of the three organs and me-
tastasize to the other(s) or to the transverse mesocolon or 
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colon have been considered to be categorically nonre-
sectable. 
During the last year, we have examined the premise 
that radical excision of most of the foregut (Fig. 1) could 
allow complete removal of certain hepatic duct cell, duo-
denal, gastric, and pancreatic malignancies that had al-
ready spread to the liver, as well as extirpation of primary 
liver tumors whose spread was downward. Ten patients 
with these seemingly untreatable conditions underwent 
removal of the liver, stomach, spleen, pancreas, duo-
denum, proximal jejunum, terminal ileum, and ascending 
and transverse colon (Fig. IB). The void in the upper 
abdomen was filled with cadaveric organ cluster grafts 
that included the liver, pancreas, duodenum, and variable 
amounts of proximal jejunum. 
Methods 
Case Material 
The patients were 27 to 46 years old with an equal 
distribution between sexes (Table 1). None of the patients 
had liver failure, although six were jaundiced (Table 1). 
All had some weight loss, which was severe in two patients. 
Severe portal hypertension was not present in any of the 
patients. 
Five of the ten patients had not been previously oper-
ated on or instmmented, and only one had received che-
motherapy (Table 2). Patient 7, a 29-year-old physician, 
had undergone resection of a superiorly located duct cell 
carcinoma (Klatskin tumor) with Roux-Y biliary recon-
stmction 2.5 years earlier. The tumor recurred with large 
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FIGs. IA AND B. (A) Delineation in embryonal life of that region of the gastrointestinal tract (dark shaded) that was resected in the organ cluster 
operation. E = esophagus, LB = lung bud, L = liver, and P = pancreas. (B) The adult organs deriving from the shaded primitive analage. 
hepatic metastases, invasion ofthe Roux limb, obstruction 
of the bile duct, and liver abscess formation (Fig. 2 lower). 
The patient was moribund from uncontrolled sepsis at 
the time of the exceptionally difficult cluster operation. 
The problems of performing an organ cluster operation 
under these circumstances were illustrated when another 
patient (not included in this series) bled to death during 
preparation for a liver transplantation or possible cluster 
7 years after right hepatic trisegmentectomy for a fibro-
lamellar hepatoma. 
Tumor Pathology 
Duct cell carcinomas were the most common (six ex-
amples); two of these were associated with sclerosing 
cholangitis (Table 2). There were two examples each of 
sarcomas and carcinoids. The liver was affected in all pa-
tients (Table 2, Figs. 2 to 5). The involvement of other 
tissues and organs is summarized in Table 2. One week 
after operation, patient 3 was found by CT scan to have 
multiple pulmonary lesions that probably predated trans-
plantation. The patient refused a lung biopsy. 
The Donors 
Eleven donors who were 14 to 37 years old provided 
the organ clusters for the 10 recipients (Table 3). Six of 
the 11 donors had minor liver function abnormalities. 
Special attention was paid to the glucose and amylase 
determinations. Two donors had significant hyperamy-
lasemia (Table 3); all donors were hyperglycemic (Table 
3). Patient 7, who has B blood type, was so ill that an 0 
donor was accepted. Patient 6 was A blood type, but when 
his first graft of the same ABO type failed, retransplan-
tation was carried out with an 0 donor. With these ex-
ceptions, all donors had the same blood type as the re-
cipients. No attention was paid to HLA antigen matching, 
TABLE 1. Recipient Patients 
Preoperative Liver Function 
Age/Sex/ Prothrombin Date of 
Number Race Bilirubin Albumin Time Operation 
1 27MW 2.3 3.6 11.3 7/22/88 
2 31 FW 0.6 3.8 12.9 7/28/88 
3 35 FW 3.2 4.2 13.0 8/26/88 
4 43MW 0.6 3.6 10.7 9/17/88 
37FW 0.3 3.8 11.9 10/27/88 
6 27MW 0.3 1.9 13.9 11/23/88 
11/26/88 
7 29 MW 9.3 2.9 14.0 11/25/88 
8 30MW 6.0 4.8 15.3 12/01/88 
9 46FW 14.0 3.1 13.2 1/01/89 
10 40FW 8.9 3.6 10.5 1/12/89 
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and the average number of matches with the recipient 
was only 1.1 of a possible 6 (Table 3). Cytotoxic cross-
matches were negative. 
In eight procurements in which the local donor team 
would permit it, 10 to 20 mgm OKT3 were given during 
the preliminary dissection as prophylaxis against graft-
versus-host disease (GVHD). The antilymphocyte anti-
body has been shown to localize in graft lymphoid tissue,2 
and crude antilymphocyte serum (ALS) has been dem-
onstrated to prevent GVHD in rodents.3 In six of the 11 
procurements, an intravenous bolus of 200 micrograms 
SandozstatinR (Sandoz Pharmaceuticals, Division of 
Sandoz, Inc., East Hanover, NJ) was given during pro-
curement to minimize the risk ofpancreatitis.4 
Donor Operation 
The donor operation (Fig. 6) was modified from the 
standard multiple organ procurement procedure.5 In dis-
secting below the transverse mesocolon, the middle colic 
artery and vein were ligated and divided, as were all 
branches of the superior mesenteric artery and vein distal 
to the blood supply of the proximal jejunum (Fig. 6). The 
upper abdominal aorta was crossclamped at the dia-
phragm, and the organ cluster graft and the kidneys were 
cooled in situ with 1500 to 2000 mL of University of 
Wisconsin (UW) solution.6 Cooling with aortic infusion 
quickly chills the splanchnic venous effluent as welU As 
an extra precaution, the liver was further chilled by in-
fusing 500 to 1000 mL UW solution through a superior 
mesenteric vein (Fig. 6, insert). A Carrell patch containing 
the origin of the celiac axis and superior mesenteric artery 
was removed with the specimen (Fig. 6). The specimen 
was immersed in UW solution, packed in an ice chest, 
and brought to Pittsburgh for further dissection and prep-
aration of vascular cuffs for eventual anastomosis. 
Six of the 11 donors also provided hearts, and all 11 
provided kidneys. The hearts were not used in some cases 
because of cardiovascular instability and the need for 
pressors (Table 3). The mean preservation time was 11.1 
± 3 (SO) hours (Table 3). 
Recipient Operation 
When time permitted, the intestinal tract of the recip-
ient was purged with GolytelyR solution (Braintree Lab-
oratories, Braintree, MA) and a bowel prep was carried 
out with oral gentamycin, polymyxin E, and nystatin. A 
bilateral subcostal incision was made with upper and lower 
midline extensions. Dissection was begun below the 
transverse mesocolon by skeletonizing the superior mes-
enteric artery and vein. The iliocolic and middle colic 
artery and vein were ligated and divided, as were numer-
ous pancreatic and duodenal branches of the superior 
mesenteric vessels. The bowel was transected at the ter-
minal ileum, splenic flexure of colon, and jejunum beyond 
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the ligament of Treitz, taking care that there were good 
pulsations in the mesentery of the retained bowel. The 
transverse colon, spleen , and pancreas were mobilized to-
ward the right, exposing the proximal portion of the su-
perior mesenteric artery, which was further cleaned from 
the left lateral approach. The aorta was dissected free and 
the celiac axis was ligated at its origin in most cases, or 
more distally in two patients in whom the left gastric artery 
and proximal stomach were retained. In the other eight 
patients, the stomach was transected at the esophagogastric 
junction (Figs. 7 and 8) or just distal to this, leaving a 
small cuff of stomach that received its blood supply from 
above. 
By completing the mobilization from left to right and 
by also mobilizing the ascending and transverse colon 
superiorly, the inferior vena cava was exposed and encir-
cled above the entrance of the renal veins. Both on the 
left and right sides, the Gerota's fascia was taken with the 
FIGS. 2A AND B. (A) CT scans or two patients with advanced duct ce ll 
carcinomas, biliary obstruction, and multiple parenchymal metastases. 
The pathologic condition orthe tumor was highly unravorable in patient 
3 (see Table 2). Note the Courvoisier gallbladder (arrow). (B) Patient 7 
had massive recurrence or a KJatskin tumor that had been resected 2.5 
years berore. This patient had liver abscesses and was dying or uncon-
trollable sepsis. 
FIGS. 3A AND B. CT scan showing the massive li ver metastases in (A) 
patient 4 and in (B) patient 5. The cell types were spindle cell sa rcoma 
and carcinoid, respectively. 
specimen or left behind as dictated by the location and 
degree of penetration of the tumor. 
The excised specimen included the liver, nearly all of 
the stomach, spleen, pancreas, duodenum, proximal je-
junum, terminal ileum, and ascending and transverse co-
lon (Fig. I B). The retrohepatic vena cava was removed 
with the specimen. The void in the upper abdomen was 
filled with a composite graft of the liver, pancreas, and 
duodenum, plus small segments of the proximal jejunum. 
The upper and lower vena caval anastomoses were per-
formed first, followed in most cases by placement of the 
Carrell patch at the site of the recipient celiac axis (Fig. 
7). Venous outflow for the intestines during removal of 
the specimen and performance of the first three vascular 
anastomoses was provided with a pump-driven veno-ve-
nous bypass that did not require heparinization (Fig. 7, 
insert). 
After rearterializing the graft, the recipient's superior 
mesenteric artery was crossclamped to prevent acute ve-
nous hypertension, the catheter in the superior mesenteric 
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vein was removed, and an end-to-end anastomosis was 
made of the donor and recipient superior mesenteric veins 
(Fig. 8). 
Gastrointestinal reconstruction usually was performed 
as shown in Figure 8. After closing the duodenal stump, 
the end of the graft jejunum was anastomosed to the side 
of the host jejunum downstream from the jejunal anas-
tomosis to the esophagus or gastric cuff. In Patient 5, 
whose proximal stomach was saved with an intact left 
gastric artery supply, the duodenum and proximal je-
junum were placed in continuity with the gastrointestinal 
tract so that ingested food passed through the homograft 
intestine as soon as eating was resumed (Fig. 9). In this 
case the Carrel patch was attached to the recipient aorta 
in the infrarenal location (Fig. 9, right). Other gastroin-
testinal reconstructions, used one time each, are shown 
in Figure 10. The hand-in-glove technique (Fig. lOA) was 
made necessary in patient I when the duodenum of the 
organ cluster developed hemorrhagic necrosis and had to 
be completely removed. 
Blood loss was 16.8 ± 9 (SD) units (range, 6 to 27), the 
large losses reflecting coagulopathies that developed during 
removal of the huge specimen or shortly after revascu-
larization of the organ cluster. In either circumstance, the 
dominant abnormality was fibrinolysis, which in some 
cases required treatment with epsilon amino caproic acid 
(EACA). 
Postoperative Care 
FIG. 4. cr scan of patient 
9, who had a very exten-
sive carcinoma of the 
common duct with liver 
invasion. and with direct 
invasion of the head and 
body of the pancreas 
(arrow). Multiple lymph 
node metastases can be 
seen. 
Immunosuppression. Baseline treatment was with cy-
c1osporine and prednisone to which azathioprine was 
added when and if the white blood count was more than 
5000 mm 3 (Figs. II and 12). The drugs were started in-
travenously and switched to the oral route when feasible. 
All ten patients had a prophylactic 10-to-14 day course 
of OKT3 starting the day of or the day after operation. 
Adjuvant cancer therapy. No other treatment than re-
section was given. 
Diet. Eating was resumed when requested by the pa-
tient, and advanced quickly to multiple small feedings. 
SandozstatinR • All ten patients were treated during op-
eration and for seven to 21 days afterwards with the syn-
thetic somatostatin, SandozstatinR, which has been shown 
to minimize experimentally caused pancreatitis.4 Intra-
venous doses were 150 micrograms every eight hours. Be-
cause SandozstatinR reduces the absorption of enteral cy-
closporine,8.9 unusual reliance was placed on monitoring 
cyclosporine blood levels, and on intravenous supple-
mentation of the cyclosporine, when indicated. 
Results 
Mortality 
Two patients died after nine and 112 days. In patient 
I, hemorrhagic necrosis of the complete duodenum ne-
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FIGS. 5A A ND B. (A) The CT scan of patient 2 whose upper abdomen 
was filled with spindle cell sarcoma at the time of operation. (B) The 
tumor-laden liver is the structure to the left of the operating room pho-
tograph. Most of the right diaphragm was removed with the specimen. 
The transverse colon is marked with white arrows. The margins were 
free of tumor, and none of the 38 lymph nodes studied had metastases. 
cessitated biliary and pancreatic reconstruction with a 
hand-in-glove jejunal anastomosis over the bare head of 
the pancreas (Fig. lOA). T his anastomosis leaked and the 
fistula could never be closed until death 112 days after 
transplantation from multiple infections, including a ce-
rebral infarction that we believe was caused by a fungus. 
Autopsy was denied. 
Patient 6 had primary nonfunction of the liver and 
severe graft pancreatitis, necessitating retransplantation 
three days after the first operation. The cluster graft was 
necrotic. Sheets of Candida albicans were already present 
in the abdomen by the time of retransplantatioo. The 
patient developed multiple brain infarcts within a few 
days, and he died nine days after transplantation. There 
were findings of systemic candidiasis and multiple organ 
failure at autopsy, including extensive ischemic damage 
to the organ cluster graft. 
TABLE 3. FeaLUres 0/ J J Donors/or Ten Recepienl Palienls 
Characteristics 
Age 
(range, 14 to 37 years) 
Race 
White 
Sex 
Male 
Female 
Cause of donor death 
Trauma 
Nontraumatic 
Pressor support 
Amylase> 100 IU 
SGPT> 50IU 
(127 ± 54, range 62 to 200) 
Blood sugar 
(range, 161 to 300) 
Total ischemia 
(range, 6 to 15.8 hours) 
HLA matches 
(range, 0 to 3) 
Number 
23. I ± 8.7 years (SO) 
II 
6 
5 
7 
4 
6 
2 
6 
216 ± 53 (SO) 
11.1 ± 3 hours (SO) 
1.1 I (SO) 
* All J I donors gave kidneys; six gave hearts. The other hearts were 
not used because of donor instability or Jack of need. 
SGPT, serum glutamic-pyruvic transaminase (serum alanine ami-
notransferase ). 
Survival 
Eight of the ten patients are alive from 3 to almost 9 
months after transplantation (Table 4). Patient 7 required 
FIG. 6. Removal of organ cluster graft from donor. The specimen is 
initially cooled with an aortic infusion of UW solution after crossclamping 
the proximal abdominal aorta. Once the specimen has been removed 
with a Carrel patch containing the origin of the celiac axis and superior 
mesenteric artery (SMA), the liver is secondarily perfused on the back 
table with UW solution (insert) through the superior mesenteric vein 
(SMV). 
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FIG. 7. Appearance of the recipient operation after removal of the host 
organs under veno-venous bypass (insert), insertion of the cluster graft, 
completion of the vena caval anastomoses above and below the liver, 
and anastomosis of the Carrel patch to the aorta at the natural location 
of the celiac axis. CA = celiac axis, SMA(D) = superior mesenteric artery 
of the donor, SMA(R) = superior mesenteric artery of the recipient , 
SMV(D) = superior mesenteric vein of the donor, and SMV(R) = superior 
mesenteric vein of the recipient. 
4 months hospitalization because of multiple enteric fis-
tulas following lysis of extensive adhesions at the time of 
transplantation. The other seven patients were discharged 
from the hospital after an average of 43 ± 17.6 (SD) days 
(range, 23 to 74 days). 
Nutrition and Metabolism 
Gastrointestinal jitnction. The eight surviving patients 
eat well enough to support their nutrition, and all eat five 
or six small meals each day. Weight loss was universal 
early after operation (Table 4), but body weight has sta-
bilized or started to increase in all patients. Stools range 
from one to four per day. Two patients have occasional 
pain with eating. Early satiety has been a complaint of 
only one patient. 
Liver function. The liver function is normal or nearly 
normal in the eight surviving patients (Table 4). 
Pancreas. None of the surviving patients have required 
insulin at any time. All patients had perioperative hyper-
amylasemia, and the first graft of patient 6 had pancreatic 
necrosis. A pancreatic fistula caused the death of patient 
I. Two of the eight surviving patients had significant 
complications of pancreatitis. Patient 4 had a pancreatic 
fistula that was drained with a pigtail catheter with reso-
lution in I week. The pancreas in patient 7 required several 
operative debridements. Pancreatic enzyme supplemen-
tation is not being provided for any patient. 
Cycfosporine absorption. The oral dose of cyc1osporine 
for the eight surviving patients after 3 to 9 months is 700 
± 470 (SO) mg per day (range, 350 to 1800 mg) to main-
tain a 12-hour trough level of 500 to 1000 ngjmL. This 
average dose is not much different than that which is given 
to the average liver transplant recipient who has been fol-
lowed for comparable periods. 
Tissue Studies 
Postoperative liver biopsies were obtained from the ten 
patients. Mild rejection was present in five patients during 
the first few weeks. After its successful treatment, cyto-
megalovirus (CMV) infection was strongly suspected or 
confirmed in these same recipients. Compared to the liver, 
which is transplanted alone, 10 these hepatic grafts had an 
unusual number of eosinophiles and neutrophiles in the 
FIG. 8. Completed superior mesenteric vein reconstruction and usual 
gastrointestinal reconstruction. 
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FIGs. 9A AND B. (Al Gastrointestinal series obtained in patient 5, six days after operation, showing homograft duodenum and jejunum in continuity 
with the patient's own stomach and jejunum. (Bl Technique used. To preserve the recipient celiac axis and left gastric artery, it was necessary to 
place the donor Carrel patch below the left renal vein and the recipient superior mesenteric artery. 
portal tracts and in the sinusoids. Kupffer cell hypertrophy 
and/or pigmentation also was common. Two pancreas 
biopsies had no signs of rejection . 
The transplanted duodenum of patient 5 was biopsied 
through an endoscope 3 weeks after operation, ten days 
after obtaining the gastrointestinal series shown in Figure 
9. Although cellular rejection was diagnosed, immuno-
suppression was not increased because liver function was 
stable (Fig. II). Two months later, another biopsy at a 
time when the patient had no eating difficulties showed 
FIGs. IOA-C. Alternative methods of reconstruction used for (Al patient I, (B) patient 2, and (Cl patient 3. 
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FIG. II. The course of patient 5 (see also Figs. 3 and 9) who was treated 
with cyciosporine, prednisone, azathioprine, and OKT3. She was dis-
charged from the hospital in 3.5 weeks. Bx = biopsy, Tx = transplantation. 
diffuse replacement of the mucosa by granulation tissue. 
These histologic findings were similar to, although less 
severe, than those reported in the duodenum after pan-
creaticoduodenal homotransplantation for diabetes mel-
litus. ll 
Evidence ofGVHD was searched for in intestinal biop-
sies of seven recipients and in skin biopsies of four of 
these patients. Most of the recipient gastrointestinal tissue 
had minimal and generally nonspecific deviations from 
normal. Sixteen days after operation, the jejunum of pa-
tient 9 contained a nodular aggregate of blastic mono-
nuclear cells that were thought to be suspicious for an 
occult lymphoproliferative disorder, especially because 
atypical B lymphocytes were found at the same time in a 
cervical lymph node biopsy. Donor mononuclear cells in 
the skin and lymph node were looked for with donor-
specific anti-HLA monoclonal antibodies, but these could 
not be found. Two months later a mild esosinophilic in-
filtrate was the only abnormality in a repeat jejunal biopsy. 
All four skin biopsies, which were performed because 
of a skin rash, had similar features that were not diagnostic 
of GVHD but which did not rule out this diagnosis. The 
blood vessels of the superficial dermis were surrounded 
with a mild inflammatory infiltrate oflymphocytes, neu-
trophiles, and eosinophiles. There was mild lymphocyte 
infiltration into the overlying epidermis and hair follicles 
in patient 9 with increased epithelial mitoses. However 
the features diagnostic of GVHD, acidophilic necrosis 
(apoptosis) and the surrounding of epithelial cells by lym-
phocytes (satellitosis), were not prominent findings. A 
lymphoproliferative skin lesion in patient 1, which was 
Epstein-Barr nuclear antigen (EBNA) positive, melted 
away when immunosuppression was lightened. 
Why eosinophiles were present in host (intestines and 
skin) as well as graft (liver) biopsies was not clear, but 
these could have been due to drug reactions, unusual 
variations of rejection or GVHD, or manifestations of 
circulating antigens or lymphokines. 
Tumor Recurrence 
Autopsy was denied for patient 1, who died 112 days 
after operation, making it impossible to rule out residual 
tumor. In patient 6, who died after nine days, no tumor 
was found at autopsy. 
None of the eight patients who are living have proved 
recurrent tumor after 3 to almost 9 months. However 
patient 3 had a CT scan of the chest eight days after op-
eration that showed multiple pulmonary nodules that were 
thought to be metastases that predated transplantation. 
However these have not changed in the ensuing 7 months 
and they may have been pulmonary emboli from the 
veno-venous bypass. This patient recently underwent an 
exploratory laparatomy for intestinal obstruction from an 
adhesive band. There was no evidence of tumor in the 
abdomen. 
Discussion 
The early success of these operations has been gratify-
ing. However it remains to be seen if the natural behavior 
of the tumors is favorably influenced. The marriage of 
transplantation and therapeutic oncology has been trou-
bled. Metastases have occurred in the vast majority of 
patients treated with total hepatectomy and liver replace-
ment for otherwise nonresectable hepatomas and hilar 
duct cell carcinomas.12 It has been suggested, although 
not proved, that the drugs given to prevent homograft 
rejection could enhance the growth of microscopic me-
tastases and actually reduce survival in spite of a successful 
transplant operation. 13 The metastases in these hepatic 
recipients began to appear within 3 months, after homing 
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FIG. 12. The course of patient 
4, whose organ cluster graft 
sustained a very severe isch-
emic injury as reflected in the 
high SGOT. The same gen-
eral immunosuppression was 
used as in Figure II. The fe-
brile episodes were attribut-
able to cytomegalovirus 
(CMV) infection of the re-
cipient intestinal tract, as well 
as of the cluster graft. Bx 
= biopsy, BAL = bronchoal-
veolar lavage. 
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to the new liver12,13 and contributing steadily to the mor-
tality at all times from 3 months onward. 12- 14 Because 
our eight surviving patients are free of detectable metas-
tases after 3 to 9 months, the next few months will be 
crucial for establishing tumor prognosis. 
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Freedom from metastases in these patients can not be 
explained solely by the selection of candidates who had 
slow-growing tumors with favorable patterns of spread. 
Six of the ten patients had duct cell carcinomas. These 
lesions have had a dismal prognosis after liver transplan-
TABLE 4. Liver, Pancreas, and Gastrointestinal Function 
Latest Postop. Liver 
Function 
Insulin or Weight 
Bilirubin Albumin Protimc Enzyme Early Pain with Stools/ Follow-up 
Patient (mg %) (gm %) (sec) Replacement Prcop Lowest Now Satiety Eating day (days) 
I 2.2 3.5 15 148 112 died 
2 0.8 3.8 11.2 0 108 95 101 no only with 1* 258 alive 
big meals 
3 0.8 4.0 13.1 0 127 93.5 93.5 no no 1-2* 231 alive 
4 0.2 3.5 11.8 0 140 112 117 no no 2 207 alive 
5 0.7 3.6 12.7 0 159 137 137 occasionally no 3-4* 168 alive 
6 16.0 3.3 13.8 168 9 died 
7 1.3 3.5 13.0 0 141 110 112 no no 2-3* 139 alive 
8 0.4 4.0 11.8 0 140 95 108 yes no 3* 133 alive 
9 1.2 3.3 12.2 0 93 78 80 no no 2* 101 alive 
10 0.5 4.0 12.0 0 168 140 140 occasionally occasionally 3* 90 alive 
* Treatment for diarrhea with dyphenoxylate HCL (patients 2, 3, 5, and 9), ioperamide HCL (patients 7, 10), and propantheline bromide 
(patient 8). 
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tation alone, even when they were far smaller and less 
advanced than those of the present series. 12 The biologic 
behavior of sarcomas and carcinoids tumors may be 
somewhat less aggressive, 15 but these tumors were mul-
tifocal and extensive in our patients. Iftumor control has 
been achieved, it will support the logic of foregut resection. 
Further experience will be required, then, to determine 
which of the foregut tumors might be appropriate for this 
kind of treatment. Neoplasms such as pancreatic acinar 
adenocarcinoma, for which present treatment is usually 
futile, even without hepatic metastases,IS could be on the 
list of possibilities. 
The idea of such radical treatment was beyond com-
prehension before the availability of transplantation made 
replacement of excised vital organs possible. The liver 
and pancreas combination is a natural unit. The subtle 
metabolic and hormonal interplay between the liver and 
pancreas is so important and wide ranging that virtually 
no aspect of liver structure, function, or the capacity for 
regeneration can be understood without considering the 
moderating role ofthe pancreas. 16,17 Nevertheless there is 
an option of doing the same extensive resection with 
transplantation of the liver alone, and we have done this 
in one patient who was too sick to wait for a cluster donor 
and for whom a liver became available. The penalty of 
using the liver alone is the creation of diabetes mellitus, 
but on the positive side, the considerable morbidity and 
mortality associated with the transplanted pancreas can 
be avoided. 
In addition to its specific potential use, the organ cluster 
operation can be a pathfinder for other visceral trans-
plantation procedures, possibly including the so-called 
multivisceral transplantations that differ from the organ 
cluster operation in that the stomach is included at the 
upper end of the graft and the rest of the small intestine 
and colon is included at the lower end. All of the muItivis-
ceral recipients who survived their operations to date died 
later when they developed the lymphomas (lymphopro-
liferative disordersf·18 that are associated with Epstein-
Barr virus infections. 19,2o Lymphomas were not seen in 
any of the ten cluster recipients, with the possible excep-
tion of patient 1. Duodenum and segments of jejunum 
have not caused problems in the surviving patients, and 
in one organ cluster recipient, who is alive 5.20 months 
after operation, all oral intake passes through a duode-
nojejunal segment before reaching the native small bowel. 
However this homograft small bowel has been seriously 
damaged by rejection, more so than the liver or pancreas 
in the cluster. The preferential susceptibility of the small 
bowel to rejection has been described before in pancrea-
ticoduodenojejunal grafts. II Thus practical exploitation 
of intestinal homotransplantation beyond short segments 
such as those in cluster grafts will require better immu-
nosuppression. We are deferring attempts to transplant 
larger grafts of hollow viscera until that time. 
When any large organ complex that contains lymphoid 
tissue is engrafted, lethal GVHD can be produced, as was 
recognized long ago after multivisceral grafts in dogs21 
and studied decisively by Monchik and Russell in Fl hy-
brid rats undergoing intestinal transplantation.22 Avoid-
ance ofGVHD has prompted us to deplete the lymphoid 
tissue of the grafts by giving OKT3 to multiviscerat2 or 
organ cluster donors. Shaffer et al. 3 have proved the effi-
cacy of this approach in rats using antilymphocyte serum. 
A special kind of GVHD can be produced when a donor 
and recipient are of different, although compatible, ABO 
blood types (0 donor to B recipient, for example).23 Then 
the lymphoid tissue can produce isoagglutinins that hem-
olyze the recipient's red blood cells. Patient 7 in our organ 
cluster series who was B blood type received an 0 organ 
and survived despite a series of catastrophic surgical com-
plications. The ability to control his humoral GVHD was 
encouraging, as was the absence of manifestations of clas-
sical GVHD in any of the other recipients. 
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DISCUSSION 
DR. FRANCIS D. MOORE (Boston, Massachusetts): Tom Starzl is one 
of the great innovators in transplant science of the world. This is one of 
the major new surgical fields of this century, previously only a dream. 
It was first reported to this society by Dr. Joseph Murray 32 years ago 
in 1957. It is a field of science and surgery to which many fellows of this 
society (many of them here this morning, including our distinguished 
President) have contributed in a very major way. This new field of surgery 
has had a world-wide impact that we scarcely can believe. 
Tom, you recently reported a procedure like this, but including the 
colon, in two young patients with nonmalignant disease (as you just 
mentioned), both of whom died. 
My first question is: what was the time relationship of those two ex-
periences to this new series? There are ten cases here, operated sometimes 
at the rate of one or two a month in 1988, I believe. Is this series still 
expanding? You have suggested in your paper that it is, and if so, at 
about what rate? 
One of those other patients with the nonmalignant disease, as you 
described in the literature, died after almost I year of survival, of a T-
cell lymphoma associated with the Epstein-Barr virus (EBV). 
My second question is: how was this EBV lymphoma obviated in this 
series? Was it by avoidance of transplantation of the terminal ileum and 
the ileal lymph nodes, by a different choice of immunosuppressive drugs, 
or was it just a matter of the age of the patients? As you have so clearly 
indicated, these are operations for cancer, sometimes cancer in the liver. 
Clearly we cannot judge whether the game is worth the candle until 
many more moons have set. 
My third question, therefore, is what is the record of liver transplan-
tation in hepatic malignancy? Can we expect anything better here? Cer-
tainly surgery has learned the hard way in the last 50 years that heroic 
technical extension of anatomic extirpation of malignant tumors rarely 
succeeds when lymph nodes are already involved. 
Do you think that will be limiting here, or were many of these really 
primary local tumors and not all of them with lymph node involvement, 
as your slides suggest? 
The removal of multiple organs for cancer is not new. Look at Alex 
Brunschweig and his pelvic clean-out operations, now a half century ago. 
Look at radical neck dissections, radical pancreatectomy, radical ne-
phrectomies, and radical pneumonectomies. Replacement of multiple 
organs by transplantation is not new either. Yesterday President Najarian 
told us about pancreas and liver grafts, pancreas and kidney grafts. But 
this upper abdominal clean-out (which might be thought of as the general 
surgeon's daydream, or possibly nightmare) is new. It is most remarkably 
interesting, especially because, as shown by those other two cases, that 
done in this manner small bowel transplantation works and provides an 
absorptive nutritional surface despite its potential for GVH reactions 
and possibly EBV lymphoma. 
Fourth, a sort of social or philosophical question that every fellow of 
this society must have on his or her mind: who should do this operation? 
Dr. Starzl, you have remarkable "field strength" here, a team, a donor-
hospital network, vast experience in every detail, and can show us this 
amazing series with eight survivors at 6 to 9 months. We know that 
others will not easily or quickly match this record. The skill factor in 
surgery is the great unmeasurable and unpredictable factor in outcome, 
and may be unteachable. Our President suggested that perhaps it is 
teachable. Sometimes I wonder. Like virtuosity in performance of a Bee-
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thoven concerto, such surgical skill is partly inborn, partly a result of 
immense self-discipline and determination: instructable, yes, but certainly 
not teachable to your average raw recruit. 
So my last question is: are we correct in addressing caution to the 
surgical world as these procedures are reported publicly and openly, an 
openness so much a part of the Starzl tradition? Are we right in saying 
to the surgical world, "hold off and wait a bit"? 
DR. JOHN S. NAJARIAN (Minneapolis, Minnesota): I would just like 
to add another word to what Frannie has so eloquently stated. The history 
of extended radical extirpative procedures has been fraught with problems. 
The major problem has usually been recurrence of tumor. Just performing 
a liver transplant alone, we know that tumor recurrence is quite common 
with hepatomas. We were hoping that the KIatskin tumor, cholangio-
carcinoma of the bile ducts at their bifurcation, was perhaps the most 
favorable of all primary liver tumors. Yet after transplanting a liver into 
three of these patients, with no lymph node metastasis found, within 12 
to 18 months all three patients had recurrence of their disease and even-
tually succumbed. 
I just would like to ask Dr. Starzl whether looking at this series at 6 
and 9 months is like looking at the fellow who has jumped out of the 
window of a tall building; as he is falling down, somebody asks, "How 
are things going?" and he replies "Not bad so far." Are we going to see 
recurrence in these patients within 1 year, or perhaps 2 years? Is it now 
time to stop and perhaps wait to see if a similar fate with early recurrence 
will occur? 
DR. THOMAS E. STARZL (Closing discussion): First let me say how 
touched and encouraged I was today by the remarks of Dr. Moore, just 
as I was almost 25 years ago at the meeting of the American Surgical 
Association when we presented our first paper to this group on the subject 
ofliver transplantation (Ann Surg 1964; 160:411-438). 
In responding to Dr. Moore, if! could, I would like to say something 
that goes back to yesterday when we heard how liver transplantation 
can, and really has, influenced the use of older operations such as the 
Kasai procedure or the Warren shunt. Bickering over these magnificent 
papers, which were given by Lilly and Henderson, would obscure the 
important point, as both of those authors yesterday emphasized, that 
liver transplantation has radically changed, and I believe forever, the 
way that any lethal liver disease will be treated. 
This is what Frannie Moore and I really hoped for, or perhaps dreamed 
of, almost 31 years ago this coming June and July, when we first worked 
on this operation in our laboratories in Boston and Chicago unbeknownst 
to each other. So you can imagine my gratification at hearing these dis-
cussions yesterday, and also my warm feeling in listening again, as I did 
so long ago, to what Dr. Moore said. Today we are looking at the same 
general question of what the role will be of this larger operation that 
essentially is an extended liver transplantation for a different indication, 
namely, the treatment of cancer. As Dr. Najarian has pointed out, we 
have a somewhat more clouded crystal ball about the potential of this 
approach and of course, it is not surprising to any of us that Dr. Moore 
has asked all of the critical questions. 
The problem with the Epstein-Barr virus lymphomas that we saw with 
our multivisceral transplantations (JAMA 1989; 26:1449-1457) has 
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seemed to us largely to be a problem of the pediatric recipient. The 
multi visceral recipients were children. The organ cluster recipients pre-
sented today are adults. Nevertheless I was intrigued to hear the hypothesis 
that this could be an organ-specific problem, and that a specific genesis 
of it could be the intestine and its lymphoid tissue. Except for the duo-
denum, the bowel is not part of the organ cluster transplant, and Dr. 
Moore's speculation that this would explain the freedom from the Epstein-
Barr lymphomas is an interesting one. 
I agree completely with both discussants that we have to wait to see 
what is going to come from this operation. Dr. Najarian's analogy might 
not be exactly in focus. The real situation was more like scooping in a 
patient who was already falling, and then determining if it is going to be 
necessary to push him back out of the window. When the patients were 
first seen by us, they already were in free fall. 
As far as the skill factor is concerned, I have learned a certain amount 
of humility in my life. Once I took too much pride in what I did and 
assumed that a skill factor was something uniquely possessed by me. 
Then I found that all of the people whom I trained and who went out 
on their own to do liver transplantations and before that kidneys, obtained 
better results than I did, and have fewer complication, or at least they 
report them that way. (Laughter) I am sure, President Najarian, that this 
will not have escaped your notice because, in discussing the paper from 
Minnesota on pancreas transplantation that was given yesterday, everyone 
who rushed to the podium had vastly better results than your own group. 
(Laughter) But they all paid homage to you, and I give them credit for 
that. 
Dr. Moore reflected on whether the organ cluster operation was a 
general surgeon's dream or nightmare. I would like to suggest that it 
might be at the nightmare end of the spectrum. In the first cases, I did 
both the donor and recipient procedures because it was an operation 
that had to be worked out. I could hardly wait to train other people to 
do the respective operations, first in the donor and then in the recipient. 
It really was beyond my physical capability. And this is by way of saying 
that most of these recipient operations have been done by very skillful 
members of our team, Satoru Todo or Andreas Tzakis, whom I have 
already mentioned. The donor operations are now done almost exclu-
sively by Dr. Luis Podesta. I do not want to conceal the fact that the 
skill factor largely represents their work rather than mine. 
As to tumor recurrence, I remember-and I am not telling the story 
with anything other than a sense of lingering sadness-conversations 
that I had with Dr. Najarian about a good friend of his and a chairman 
of one of the other departments at the University of Minnesota. John 
and I were in Bologna together a few years ago, and he indicated to me 
how foolish my many published articles had been about inevitable re-
currence of Klatskin tumors after liver transplantation. He told me of 
this friend who was 1 year postoperative after liver transplantation and 
in perfect condition. John called me up a week or so later and said that 
he had come back to Minnesota only to find that this man was riddled 
with tumor and that because of the nature of our discussion, he wanted 
me to know the outcome. I appreciated that expression of honesty. Now 
it will be my reciprocal responsibility to provide a full follow-up of these 
and other patients treated with the organ cluster operation. 
